How a mitochondrial diagnosis is actually made

The short version

• "Mitochondrial dysfunction" is not a diagnosis. It is a loose phrase. Mitochondrial disease is a group of rare inherited conditions with a proper diagnostic process.
• Doctors look for a pattern, not one symptom. Suspicion starts when problems show up across several body systems at once, often with a family history.
• Today, genetic testing does most of the work, and older approaches such as muscle biopsy are needed less often.
• No single test decides it. Results are read together, by specialists, and the process often takes years.
• Tiredness on its own does not point to mitochondrial disease. Fatigue has hundreds of possible causes, most of them far more common.
• Researchers are exploring mitochondria-targeted compounds such as MOTS-c and SS-31 for fatigue. That work is early and is covered below; it is a doctor conversation, not a diagnosis.

Educational content, not medical advice. This page describes how a diagnostic process has been reported in published cohorts. It does not recommend, name or endorse any test, investigation or referral as a step for any reader to pursue, and nothing here is a basis for self-assessment.

---

If you have spent time reading about persistent fatigue, you have almost certainly met the phrase mitochondrial dysfunction. It arrives with an air of explanation - a mechanism, finally, for something that has resisted one. It is also doing a great deal of unearned work. There is a real, well-characterised class of conditions called mitochondrial disease, diagnosed by clinicians in specialist settings against published criteria. And there is a much looser phrase that borrows its authority. This page is about what separates them.

What a diagnosis is, and what a finding is

A diagnosis is a determination: a clinician, working within a defined framework, concludes that a person's presentation is best explained by a specific condition, and that conclusion carries consequences for how they are cared for. A finding is narrower - an individual observation, from an examination or an investigation, that may or may not point anywhere on its own.

The distinction matters because most of what circulates about mitochondria online lives at the level of findings, or below it. A measurement that sits outside a reference range is a finding. A mechanism described in a cell model is not even that. Neither becomes a diagnosis by accumulation or by confident restatement. The step from one to the other is made by a person with clinical responsibility, and it is not a step a reader can take on their own behalf.

This is the same problem the library treats more generally in what a study actually measured - the gap between something being observed and something being established.

Why "mitochondrial dysfunction" and "mitochondrial disease" are not the same phrase

Primary mitochondrial disease refers to a group of inherited disorders in which the machinery that produces cellular energy is impaired by identified genetic changes. These conditions are individually uncommon, frequently affect several organ systems at once, and are described in a substantial clinical literature with defined diagnostic frameworks.

"Mitochondrial dysfunction" is a much broader phrase. In research contexts it describes a measurable state - reduced efficiency in some aspect of energy metabolism - that has been observed as a feature of many conditions and of ordinary ageing. Used that way it is meaningful and specific to its measurement. Used online, it typically means something closer to "tired in a way I want a biological explanation for," which is a different sentence altogether.

The reason to hold these apart is not pedantry. The first has a diagnostic pathway, a specialist community and, for some forms, established management. The second, in its loose usage, has none of those things, because it is not a diagnosis. Conflating them tends to move people away from the assessment that might actually identify what is going on. What changes in mitochondria over a normal lifespan is a separate question, covered in what happens to mitochondria as you age.

How the diagnostic process has been described in the published literature

What follows describes what has been done in published patient cohorts, in the past tense. It is included so that the scale and setting of this process are legible - not as a description of steps available to a reader.

In reported series, the process did not begin with an investigation. It began with clinical suspicion arising from a pattern: a constellation of problems across systems that do not ordinarily travel together, often with onset at a characteristic age, sometimes with a family history that fits a recognised inheritance pattern. Clinicians described assembling this picture over time, from history and examination, before any specialised investigation was considered.

Where investigation followed, published cohorts describe a layered approach. Broad metabolic assessment was typically undertaken first. Genetic analysis has become central to contemporary practice, and in many published series it has substantially displaced more invasive approaches; where it identified a causative variant, that finding carried significant diagnostic weight. Tissue biopsy, historically important and still described in the literature, has become less routinely necessary as genetic methods improved. Assessment of affected organ systems - which systems, and how - was determined by the individual clinical picture rather than by a fixed protocol.

Two features of this literature deserve emphasis. First, results were interpreted in combination and against the clinical picture, never in isolation; published discussions are consistent that no single result was treated as decisive on its own. Second, the process was frequently long and non-linear, with reported diagnostic journeys extending over years and revised conclusions along the way. Descriptions of this pathway as a defined sequence, arrived at quickly, do not match what the literature reports.

What the clinical picture has had to include

Across published frameworks, the presentations that prompted this line of inquiry shared certain features. They tended to involve multiple organ systems, particularly those with high energy demand. They tended to show objective findings on examination, not symptoms alone. They frequently involved specific, characteristic clinical features rather than general ones. And they often carried a family history or developmental history consistent with an inherited condition.

The common thread is objectivity and pattern. What appears in these frameworks is not a list of complaints but a configuration of findings a clinician could observe and document.

Why fatigue on its own does not open this door

Fatigue is among the most common reasons people seek medical attention, and it is one of the least specific symptoms in medicine. It is a feature of a very large number of conditions, most of them considerably more common than mitochondrial disease, and of a great many circumstances that are not conditions at all - insufficient or disrupted sleep, psychological distress, the aftermath of infection, and the ordinary consequences of how a life is currently arranged.

That is precisely why fatigue does not function as an entry point to this pathway. A symptom shared by hundreds of conditions cannot, on its own, distinguish between them. In the published frameworks, isolated fatigue without objective multi-system findings is not the presentation that prompts this line of inquiry.

This is not a claim that persistent exhaustion is unimportant or imagined. It is a claim about what that symptom can identify by itself, which is very little. The many things that produce it are the subject of why persistent fatigue has more than one cause.

MOTS-c and SS-31: what researchers are exploring for fatigue

This section describes research interest. It is not a diagnosis, and it is not a treatment plan.

Because mitochondria are where cells make most of their energy, researchers have asked a reasonable question: could compounds aimed at mitochondria help people with long-lasting fatigue, including chronic fatigue syndrome (ME/CFS, a long-term illness where exhaustion is severe and gets worse after effort)? Two names come up most often.

• SS-31 (elamipretide) sits on the inner membrane of mitochondria, where energy is produced. In a small randomised trial in healthy older adults, a single infusion briefly raised how much energy (ATP) their muscle could make compared with a dummy infusion, and the effect had faded a week later. In a larger trial in people with an inherited mitochondrial muscle disease (MMPOWER-3), it did not meet its main goals. SS-31 is FDA-approved only for Barth syndrome, a rare inherited condition, and it has not been tested in ME/CFS.
• MOTS-c is a small peptide that mitochondria make themselves. A 2019 study of 10 people with CFS and 10 with a related post-infection fatigue syndrome found the gene for MOTS-c was less active in their immune cells than in healthy volunteers. That is an interesting clue, not a treatment result, and MOTS-c has no completed human trial. It is investigational.

Some clinics and researchers bring these together in investigational "cellular energy" approaches; our cellular energy and longevity protocol combines SS-31, MOTS-c and epithalon. The right order matters: first a proper assessment that looks for the common, treatable causes of fatigue (our what to test page lists a sensible baseline panel), then, if you want to explore these compounds, a plan with measurements before and after. They do not diagnose anything, and they are not a substitute for the specialist process described above. For more on each, see SS-31 and MOTS-c explained and is SS-31 FDA approved?.

Who makes this determination, and in what setting

In the published literature, these diagnoses were made within specialist services - clinicians with specific training in metabolic and mitochondrial medicine, typically working in multidisciplinary teams, frequently in academic centres. Genetic findings were interpreted alongside genetics professionals, because variant interpretation is a specialist skill in its own right and the same result can carry different weight depending on context.

This is a structural point, not a gatekeeping one. The determination requires interpreting several categories of information against each other and against a clinical picture assembled over time. It is not a conclusion that can be reached from any single result, by any single person, and the literature does not describe it being reached that way.

What this means if you have been told your mitochondria are the problem

If that phrase has been offered to you - by a website, an algorithm, or anyone else - the most useful thing to understand is what kind of statement it is. In almost every case encountered online it is a mechanistic hypothesis, not a diagnosis: a proposed explanation for a symptom, not a determination made about you.

A mechanistic hypothesis is not nothing. But it is not a finding about your body, it does not carry the consequences a diagnosis carries, and it is not made more true by how well it fits the way you feel. Persistent fatigue that is interfering with your life is a reason to be assessed properly by a clinician who can take a history, examine you, and consider the full range of things that produce it - which is a much wider range than the internet's current favourite.

The risk of the phrase is not that it is frightening. It is that it feels like an answer, and a feeling of resolution is one of the more effective ways to stop looking.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial.

Frequently asked questions

Is mitochondrial dysfunction the same as mitochondrial disease? No. Mitochondrial disease is a group of inherited disorders diagnosed against defined clinical frameworks in specialist settings. "Mitochondrial dysfunction" is a broad research phrase describing reduced efficiency in aspects of energy metabolism, observed as a feature of many conditions and of normal ageing. The second is not a diagnosis, and online it usually functions as a hypothesis rather than a finding.

Can a single result confirm a mitochondrial disorder? The published literature is consistent that it did not. Results were interpreted in combination and against the whole clinical picture, and reported diagnostic pathways frequently ran for years with revised conclusions along the way. Descriptions of a single decisive result do not match what the literature reports.

Does persistent fatigue suggest a mitochondrial condition? On its own, no. Fatigue is one of the least specific symptoms in medicine, common to a very large number of conditions and circumstances, most far more common than mitochondrial disease. In published frameworks the presentations that prompted this inquiry involved objective findings across multiple organ systems, not fatigue alone.

Who makes this kind of diagnosis? Specialist clinicians in metabolic and mitochondrial medicine, generally in multidisciplinary teams and often in academic centres, with genetics professionals involved in interpreting genetic findings. It is not a determination reached from a single result by a single person.

Related reading

• Why am I always tired? · What happens to mitochondria as you age · What a biological age test measures · Research on what, in whom, measured how · How biomarker monitoring works
• Part of The Complete Guide to Mitochondrial Health

---

Educational content, not medical advice. This page describes how a diagnostic process has been reported in published patient cohorts; it is not a description of steps available to a reader, and it does not recommend or endorse any investigation. Persistent or worsening symptoms should be assessed by a qualified clinician. Claims for the Malaysian market are subject to MAB requirements.

References

• Diagnostic frameworks for primary mitochondrial disease: multi-system involvement, objective clinical findings, characteristic features and inheritance patterns as the basis of clinical suspicion; layered investigation determined by presentation; results interpreted in combination rather than individually. (Consensus diagnostic criteria and clinical review literature.)
• Shift toward genetic analysis as the contemporary diagnostic mainstay, with reduced routine reliance on tissue biopsy. (Clinical review literature.)
• Extended and non-linear diagnostic pathways, including revised conclusions over time, reported across patient cohorts.
• Fatigue as a high-frequency, low-specificity presenting symptom in primary care.
• Roshanravan B, et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLoS One. 2021. Randomised, placebo-controlled, 39 healthy older adults; short-lived rise in maximal ATP production; prespecified fatigue-resistance analysis not significant.
• Karaa A, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 trial. Neurology. 2023. Did not meet primary endpoints.
• Raijmakers RPH, et al. A possible role for mitochondrial-derived peptides humanin and MOTS-c in patients with Q fever fatigue syndrome and chronic fatigue syndrome. J Transl Med. 2019;17:157. 10 per group; reduced MOTS-c gene expression in monocytes; observational.